Clinical trial · Observational
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
A Long-term Follow-up Study in Patients Previously Treated With Mustang Bio, Inc. CAR-T Cell Investigational Products
NCT05645744CI-TRIAL-00079013terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Business Reasons
Summary
Brief summary (as posted)
A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.
Conditions
Conditions (11)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B-cell Lymphoma Refractory | — | UNRESOLVED | — |
| Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Blastic Plasmacytoid Dendritic Cell Neoplasm | ONTOLOGY_EXACT | 0.85 |
| Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia | CURATED_BROADER | 0.78 |
| Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
| Follicular B-cell Non-Hodgkin's Lymphoma | — | UNRESOLVED | — |
| Hairy Cell Leukemia | Hairy Cell Leukemia | ONTOLOGY_EXACT | 0.98 |
| Mantle Cell Lymphoma Recurrent | — | UNRESOLVED | — |
| Mantle Cell Lymphoma Refractory | — | UNRESOLVED | — |
| Small Lymphocytic Lymphoma, Relapsed | Small Lymphocytic Lymphoma |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prior MB-102 CAR-T cell investigational product. | Biological | — | UNRESOLVED |
| Prior MB-106 CAR-T cell investigational product. | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Prior MB-102 CAR-T cell investigational product.
- description
- Patients previously treated with MB-102 CAR-T cell investigational product.
- interventionNames
- Biological: Prior MB-102 CAR-T cell investigational product.
- label
- Prior MB-106 CAR-T cell investigational product.
- description
- Patients previously treated with MB-106 CAR-T cell investigational product.
- interventionNames
- Biological: Prior MB-106 CAR-T cell investigational product.
Primary outcomes (2)
- measure
- Adverse events (AEs)
- timeFrame
- Up to a total of 15 years
- description
- Incidence and characterization of adverse events (AEs) related to prior treatment with a Mustang Bio CAR-T cell investigational product received in a Mustang Bio sponsored clinical study.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients previously treated with a Mustang Bio CAR-T cell investigational product in a prior Mustang Bio sponsored clinical study. * Patient has provided signed and dated informed consent. Exclusion Criteria: * None. All patients who have received prior treatment with Mustang Bio CAR-T cell investigational product in a Mustang Bio sponsored clinical study are eligible for this long-term follow up (LTFU) study.
References
Publications (0)
Data not yet available
No reference posted for this study.